bullish

Harrow Inc (HROW) - Tuesday, Oct 31, 2023

194 Views30 Jan 2024 20:55
Syndicated
SUMMARY

Key points (machine generated)

  • Harrow is a pharmaceutical company specializing in prescription medications for ophthalmologists and optometrists.
  • The company offers FDA-approved branded ophthalmic pharmaceuticals and innovative compounded prescription medicines.
  • Harrow owns commercial rights to ten branded ophthalmic pharmaceutical products and operates ImprimisRx, a pharmaceutical-compounding business.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Value Investors Club
External reports (aggregated public sources)
Value Investors Club
Equity Bottom-UpEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • Harrow Inc (HROW) - Tuesday, Oct 31, 2023
    30 Jan 2024
x